Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

160.21B

Market cap160.21B

Price-Earnings ratio

17.36

Price-Earnings ratio17.36

Dividend yield

2.50%

Dividend yield2.50%

Average volume

7.04M

Average volume7.04M

High today

$129.53

High today$129.53

Low today

$127.02

Low today$127.02

Open price

$127.59

Open price$127.59

Volume

1.66M

Volume1.66M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$104.46

52 Week low$104.46

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $129.03, giving the company a market capitalization of 160.21B. It carries a P/E multiple of 17.36 and pays a dividend yield of 2.5%.

During the trading session on 2026-06-03, Gilead Sciences(GILD) shares reached a daily high of $129.53 and a low of $127.02. At a current price of $129.03, the stock is +1.6% higher than the low and still -0.4% under the high.

Trading activity shows a volume of 1.66M, compared to an average daily volume of 7.04M.

The stock's 52-week range extends from a low of $104.46 to a high of $157.29.

GILD News

Simply Wall St 5h

Gilead Data On Livdelzi And Trodelvy Points To Broader Future Mix - simplywall.st

...

TipRanks 1d

Gilead announces results from Phase 3 study of Livdelzi

Gilead (GILD) Sciences announced results from a Phase 3 study in people with primary biliary cholangitis, showing that treatment with Livdelzi led to significan...

Simply Wall St 4d

Gilead Sciences Valuation Check After Hepcludex Wins First FDA Approval For Hepatitis Delta

The U.S. Food and Drug Administration has granted accelerated approval for Hepcludex, the first approved treatment for chronic hepatitis delta virus infection i...

Analyst ratings

81%

of 31 ratings

Buy

80.6%

Hold

19.4%

Sell

More GILD News

TipRanks 5d

Gilead’s Lenacapavir PrEP Study: Real-World Data That Could Reshape the HIV Prevention Market

Gilead Sciences (GILD) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst rat...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.